

1 **Lipopolysaccharide composition determines the preferred route and entry**
2 **kinetics of bacterial outer membrane vesicles into host cells**

3

4 Eloise J O'Donoghue¹, Douglas F. Browning¹, Ewa Bielska¹, Luke Alderwick¹, Sara Jabbari^{1,2} and
5 Anne Marie Krachler^{3,*}

6

7

8 ¹Institute of Microbiology and Infection, School of Biosciences, University of Birmingham,
9 Edgbaston, B15 2TT Birmingham, UK

10 ²School of Mathematics, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK

11 ³Department of Microbiology and Molecular Genetics, University of Texas McGovern Medical
12 School at Houston, Houston, TX, 77030, USA.

13 *Correspondence to: Anne Marie Krachler (anne.marie.krachler@uth.tmc.edu)

14

15 **SUMMARY**

16 Outer membrane vesicles are microvesicles shed by Gram-negative bacteria and play important
17 roles in immune priming and disease pathogenesis. However, our current mechanistic
18 understanding of vesicle - host cell interactions is limited by a lack of methods to study the kinetics
19 of vesicle entry and cargo delivery to host cells in real-time. Here, we describe a highly sensitive
20 method to study the kinetics of vesicle entry into host cells in real-time using a genetically encoded
21 probe targeted to vesicles. We found that route of vesicular uptake, and thus entry kinetics and
22 efficiency of cargo release, are determined by the chemical composition of the bacterial
23 lipopolysaccharide. The presence of O-antigen facilitates receptor-independent entry, which
24 enhances both rate and efficiency of cargo uptake by host cells. Collectively, our findings highlight
25 the chemical composition of the bacterial cell wall as a major determinant of secretion-independent
26 delivery of virulence factors during Gram-negative infections.

27

28

29 **Keywords:** outer membrane vesicles, enterohemorrhagic *Escherichia coli*, FRET assay,
30 extracellular vesicles, endocytosis, vesicle trafficking;

31

32 INTRODUCTION

33 Outer membrane vesicles (OMVs) are nano-sized proteoliposomes released from the cell envelope
34 of all Gram negative species of bacteria (Haurat et al, 2015). OMV release is a highly conserved
35 process, occurring under all growth phases and environmental conditions (Bonnington and Kuehn,
36 2014). OMVs are able to contain and deliver a range of substrates, from large hydrophobic
37 molecules to DNA, making them a versatile and generalised form of secretion that enhances
38 bacterial fitness in hostile environments (Renelli et al, 2004; Kaparakis et al, 2010; Manning and
39 Kuehn, 2011; MacDonald and Kuehn, 2012). They also contribute significantly to pathogenesis,
40 via the delivery of virulence factors such as toxins, adhesins and immunomodulatory compounds
41 directly into the host cell (Alaniz et al, 2007; Lindmark et al, 2009; Roy et al, 2011). In a mouse
42 model, purified OMVs from *Escherichia coli* were sufficient to cause lethal sepsis in the absence
43 of intact bacterial cells, indicating their potency in enhancing infection and inflammatory processes
44 (Park et al, 2010). The immunogenicity and ubiquitous production of OMVs has also led to their
45 successful use in vaccine preparations, such as MeNZB against *Neisseria meningitidis*,
46 representing an application for OMVs in generating immunity against bacterial infections without
47 the risks associated with live cell vaccines (Oster et al, 2007). Whilst many virulence factors have
48 been identified as OMV cargo, the processes underlying their delivery to host cells during infection
49 are not well characterised. Understanding these mechanisms could help to identify targets for
50 inhibition of OMV-associated toxin delivery and lead to attenuation of bacterial infections, as well
51 as helping to achieve their therapeutic potential in medicine, via vaccines and engineered delivery
52 vehicles (Kim et al, 2008; Gujrati et al, 2014; O'Donoghue and Krachler, 2016).

53 Release of OMVs occurs during infection, and has advantages over other secretion systems. They
54 carry a broad range of cargo, from protein toxins such as VacA and shiga toxin, to hydrophobic
55 molecules such as *Pseudomonas* quinolone signal (PQS), the quorum sensing molecule of
56 *Pseudomonas aeruginosa*, and this cargo is protected from the potentially hostile extracellular
57 environment (Kulp and Kuehn, 2010; Berleman and Auer, 2013). OMV-mediated delivery of
58 virulence factors occurs without requiring close proximity between the bacterial cell and the host
59 cell (Bomberger et al, 2009). The small size of OMVs (20-200 nm) has made studying their
60 interactions with host cells in real time difficult. Previous work has often relied on OMVs labelled
61 with dyes such as fluorescein isothiocyanate (FITC) or dioctadecyloxacarbocyanine perchlorate
62 (DiO). While such dyes allow real time study of OMV entry and cargo delivery processes, the use
63 of membrane labelling of the vesicles may interfere with their physiological characteristics, and
64 alter the mechanism of OMV entry and cargo release (Bauman and Kuehn, 2009; Lulevich et al,
65 2009; Parker et al, 2010). Other approaches have used immunolabelling of OMV-associated
66 epitopes, such as hemolysin (HlyA) in enterohemorrhagic *Escherichia coli* (EHEC), but this
67 requires fixation of cells at pre-determined time points, and requires assumptions about OMV
68 cargo, which may ignore natural sub-populations of OMVs (Bielaszewska et al, 2013). Some
69 experiments have used host cell phenotypes as an indicator of OMV uptake, such as downstream
70 activation of NF- κ B responses in epithelial cells after incubation with OMVs from *Helicobacter*
71 *pylori* (Kaparakis et al, 2010). However, host cell responses to OMV cargo are decoupled from
72 vesicle uptake and may occur much later than the initial entry event (Wai et al, 2003). The
73 discrepancies in previous observations of OMV entry and cargo delivery may be attributable to the
74 different methods used in these studies, demonstrating the need for an assay that can detect OMV
75 entry processes in a consistent and repeatable manner. Here we describe a novel assay to

76 continuously measure OMV uptake and cargo delivery to host cells with high sensitivity, and in a
77 format that is adaptable for high throughput screening. Using this assay to study entry of EHEC
78 vesicles into host cells, we identified key bacterial and host factors that determine the route of
79 entry, and thereby kinetics and efficiency of vesicular cargo delivery to host cells.

80

81 **RESULTS**

82 **A highly sensitive and dynamic assay for monitoring entry of OMV into host cells**


83 We set out to develop an assay that would allow us to monitor entry of OMVs into host cells in
84 real-time. This assay relies on the use of a genetically encoded hybrid reporter probe that is
85 incorporated into the bacterial outer membrane and subsequently targeted to OMVs. ClyA, a
86 cytolysin that is sorted into OMVs by EHEC, acts as the targeting component, and is fused to the
87 catalytic domain of β -lactamase (Bla), which acts as an enzymatically active probe (Figure 1A).
88 Host cells are incubated with CCF2-AM, a dye composed of a covalently linked coumarin and
89 fluorescein molecule, resulting in FRET and green fluorescence emission specifically in the
90 eukaryotic cytoplasm where it is processed by esterases, while remaining non-fluorescent in its
91 extracellular form. Cytoplasmic processing also prevents the derivative from exiting the cell, thus
92 trapping the fluorescent derivative in the host cell cytoplasm. When OMVs isolated from the
93 producing bacterial strain enter host cells, their ClyA-Bla fusion cargo is able to cleave CCF2-AM,
94 which abolishes FRET and results in a detectable shift in emission from green (530nm) to blue
95 (460nm) fluorescence (Figure 1A). This shift in emission can be monitored in real time to
96 determine the rate of uptake and delivery of OMV cargo to host cells, by comparing the ratio of
97 blue to green fluorescence intensity as an indicator of OMV-host cell interactions.

98 **ClyA-Bla probes are targeted to EHEC OMVs and retain their enzymatic activity**

99 First, we set out to verify whether ClyA-Bla fusion constructs retained the ability of ClyA to
100 partition into vesicles, and were indeed targeted to EHEC OMVs. Following induction of ClyA-
101 Bla fusion protein production, OMVs were isolated from EHEC expressing either ClyA-Bla (C-
102 terminal fusion) or Bla-ClyA (N-terminal fusion). Western blotting and probing of membranes
103 with Bla-specific antibody revealed the presence of a specific band at 69 kDa, corresponding to
104 intact ClyA-Bla fusion protein in samples from EHEC whole cell lysate, supernatant and OMVs
105 following induction, suggesting that the fusion protein was targeted to and enriched in OMV
106 fractions, as previously reported for non-pathogenic *E. coli* (Kim et al, 2008), (Figure 1B). Protease
107 protection experiments revealed that the ClyA-Bla probe was oriented with Bla facing the exterior
108 of the OMV, as β -lactamase detection by Western blotting was abolished after prolonged treatment
109 of ClyA-Bla OMVs with papain, while the signal remained stable in OMVs containing Bla-ClyA
110 where Bla faces the vesicle lumen (Figure 1C). Enzymatic activity of the probes was assessed by
111 their ability to hydrolyse the β -lactamase substrate nitrocefin. The specific enzyme activity was
112 high for ClyA-Bla OMVs and lower for Bla-ClyA, and both activities were equalized by lysis of
113 vesicles and probe solubilization, suggesting efficient expression of active β -lactamase with the
114 anticipated orientation (inward facing for Bla-ClyA, outward facing for ClyA-Bla) in the isolated
115 OMV fractions (Figure 1D).

116 Transmission electron microscopy and nanoparticle tracking analysis confirmed that incorporation
117 of ClyA-Bla probes into OMVs had no observable effect on OMV morphology or size (Figure 1E,
118 F and S1). Average OMV concentration was 5×10^{12} particles per ml, with sizes ranging from 10-
119 400 nm in diameter, with a mean diameter of 134 nm. The size ranges were in accordance with

120 data obtained previously for OMVs from *E. coli* (Kim et al, 2008) and particle concentrations of
 121 all samples were normalized to give a consistent OMV concentration for subsequent experiments.




122
 123 **Figure 1. ClyA-Bla probes are targeted to EHEC OMVs and retain their enzymatic activity**
 124 (A) Expression of genetically encoded ClyA-Bla probes is induced in bacteria and secreted vesicles are isolated for
 125 subsequent experiments. Entry of enzymatically active probes into host cells can be detected using a continuous FRET
 126 assay.
 127 (B) Whole cell lysate (WCL), supernatant (sup) and outer membrane vesicles (OMV) fractions isolated from EHEC
 128 expressing ClyA-Bla, carrying empty vector, or no vector were separated by SDS-PAGE and expression of ClyA-Bla
 129 was detected by Western Blotting with α-Bla antibody.
 130 (C) OMV fractions from EHEC expressing Cly-Bla, Bla-ClyA or carrying empty vector were treated with papain for
 131 30 or 60 minutes, and used for Western Blotting with α-Bla antibody.
 132 (D) Specific enzyme activity in whole cell lysate, supernatant, OMV or solubilized OMV fractions isolated from EHEC
 133 expressing ClyA-Bla, Bla-ClyA, or carrying empty vector.
 134 (E) Electron micrographs of negative stained OMV fractions from EHEC wt or EHEC ClyA-Bla. Scale bars, 0.5 μm.
 135 (F) Nanoparticle tracking analysis of OMV fractions from EHEC expressing ClyA-Bla (red), carrying empty vector
 136 (grey) or no vector (green). Results are means ± stdev from at least 200 tracks per sample. Significance was determined
 137 using analysis of variance (ANOVA), with a Brown Forsythe test to determine equal variance. NS indicates no
 138 significant differences between samples (p value > 0.05).

139 **OMV-targeted enzyme probes report on vesicle uptake and dismantling by host cells**

140 Having verified the correct targeting, orientation and enzymatic activity of the ClyA-Bla probes,
141 we set out to use them to dissect the uptake and release of vesicle luminal contents in epithelial
142 cells. Due to their different probe orientation, ClyA-Bla OMVs report on uptake of OMVs into
143 host cells, while Bla-ClyA OMVs report on exposure of luminal cargo, or dismantling of OMVs
144 within host cells. HeLa epithelial cells loaded with CCF2-AM and exposed to EHEC ClyA-Bla
145 OMVs at a multiplicity of infection (MOI) of 1000 showed a rapid increase in FRET (and thus
146 OMV uptake) over the course of a 3 hour experiment, while Bla-ClyA caused a slower increase in
147 FRET with a notably later onset compared to ClyA-Bla. OMVs devoid of probe did not cause a
148 significant change in FRET (Figure 2A). Despite the different rates in FRET change, the total
149 decrease in FRET after 3 hours (i.e., the efficiency of OMV uptake and cargo release, respectively)
150 was similar for ClyA-Bla and Bla-ClyA, indicating both cargo uptake and vesicle dismantling were
151 complete after 3 hours (Figure 2D). The rates of FRET change were further analyzed by fitting to
152 a cubic spline function and estimating gradients. While the rate of cargo release is stable throughout
153 the experiment (approx. 0.002 s^{-1}), the rate of uptake is initially high (approx. 0.007 s^{-1}) but
154 gradually decreases and approaches the rate of cargo release (Figure 2B and C).

155
156 Confocal fluorescence microscopy of HeLa cells infected with EHEC ClyA-Bla OMVs at an MOI
157 of 1000 also showed a distinct shift from green to blue fluorescence over the course of the
158 experiment compared to uninfected cells, validating the spectral traces collected on the plate reader
159 (Figure 2E). Transmission electron microscopy of HeLa cells incubated with OMVs revealed the
160 presence of both external and internalized OMVs (Figure 2F).



161

162 **Figure 2. Reporter OMVs enter host cells, and capture dynamics of vesicle uptake and dismantling in real time**

163 (A) CCF2-AM loaded HeLa cells were exposed to OMVs from EHEC carrying ClyA-Bla (red), Bla-ClyA (green) or
164 empty vector (grey) at an MOI of 1000 for 3 hours. The FRET signal (ratio of blue:green fluorescence) over time was
165 plotted as mean \pm stdev (n=3).

166 (B) polynomials were fitted to each data set using the cubic spline function csaps in Matlab. Numerical estimates of
167 the gradients of the resulting polynomials were determined using the gradient function. Data shown are means \pm stdev
168 (n=3).

169 (C) Maximum rates were determined from data in (B) to visualize speed of uptake/cargo release. Data shown are means
170 \pm stdev (n=3) and significance was determined by analysis of variance (ANOVA), with a Brown Forsythe test to
171 determine equal variance. (**) indicates $p \leq 0.01$.

172 (D) Total FRET changes after 3 hrs were determined from data in (A) and plotted to visualize overall efficiency of
173 uptake/cargo release from OMVs. Data shown are means \pm stdev (n=3) and significance was determined by analysis
174 of variance (ANOVA), with a Brown Forsythe test to determine equal variance. (*) indicates $p \leq 0.05$, and ns (not
175 significant) $p \geq 0.05$.


176 (E) CCF2-AM loaded HeLa cells were imaged by confocal microscopy either uninfected (left), following infection with
177 EHEC ClyA-Bla OMVs at an MOI of 1000 immediately (middle) or after 4 hrs of infection (right panel). Images are
178 merged blue/green fluorescence channels and are representative of three independent experiments and 5 fields of view.
179 Scale bar, 10 μ m.

180 (F) Following incubation with EHEC ClyA-Bla OMVs for 1 hr, HeLa cells were visualized by TEM, and OMVs were
181 observed both externally and internally (red box).

182 **EHEC OMVs enter host cells more rapidly and efficiently than OMVs from non-pathogenic**

183 *E. coli*

184 Next, we compared the uptake kinetics of OMVs isolated from EHEC and the non-pathogenic *E.*
185 *coli* strain MG1655. Uptake of EHEC OMVs was faster, compared to MG1655 OMVs (Figure
186 3A); the maximal rate was higher (Figure 3B-C), and a high rate of uptake was sustained for longer
187 than for the non-pathogenic strain (Figure 3B). The total change in FRET signal was significantly
188 higher, indicating that the overall efficiency of OMV uptake was higher for EHEC than MG1655
189 (Figure 3D). The higher rate and efficiency of uptake of EHEC OMVs compared to non-pathogenic
190 OMVs were independent of OMV size, which was equivalent, or OMV concentration which was
191 normalized for both strains (Figure S1). Uptake rate and efficiency increased with OMV
192 concentration for both EHEC and MG1655, but the maximal rate plateaued at a lower concentration
193 and lower rate for MG1655 (Figure 3E, F). Taken together, these results suggest EHEC OMVs
194 contain factors absent from MG1655 OMVs that accelerate the rate and increase the efficiency of
195 vesicle uptake by host cells.



196

197

198 **Figure 3. EHEC OMVs enter host cells more rapidly and efficiently than OMVs from E. coli MG1655**

199 (A) CCF2-AM loaded HeLa cells were exposed to OMVs from EHEC carrying ClyA-Bla (red), or *E. coli* MG1655
200 carrying ClyA-Bla (blue) at an MOI of 1000 for 3 hours. The FRET signal (ratio of blue:green fluorescence) over time
201 was plotted as mean \pm stdev (n=3).

202 (B) Polynomials were fitted to each data set from (A) using the cubic spline function csaps in Matlab. Numerical
203 estimates of the gradients of the resulting polynomials were determined using the gradient function and plotted as
204 means \pm stdev (n=3).

205 (C) Maximum rates were determined from data in (B) to visualize speed of uptake for EHEC (red) or MG1655 (blue)
206 OMVs. Data shown are means \pm stdev (n=3) and significance was determined using student's t-test. (***) indicates
207 $p \leq 0.001$.

208 (D) Total FRET changes after 3 hrs were determined from data in (A) and plotted to visualize overall efficiency of
209 uptake for EHEC (red) and MG1655 (blue) OMVs. Data shown are means \pm stdev (n=3) and significance was
210 determined by student's t-test. (**) indicates $p \leq 0.01$.

211 (E) Experiments were repeated as for (A), and maximum rates determined as described above. The standard OMV
212 concentration used for experiments (A-D) gives an MOI of 1000 and corresponds to 10 $\mu\text{g/ml}$ of protein. Data are
213 means \pm stdev (n=3).

214 (F) Efficiency of uptake (total change in FRET signal over 3 hrs) was determined as described above. Data are means
215 \pm stdev (n=3) for each OMV concentration.

216

217

218 **Lipopolysaccharide O-antigen increases efficiency of OMV uptake by host cells**

219 Since OMVs are derived from the outer membrane of Gram-negative bacteria, they contain
220 lipopolysaccharides (LPS), (Cahill et al, 2015). Whilst lipid A and the core oligosaccharide regions
221 are well conserved, many species including EHEC contain a highly variable polysaccharide domain
222 known as the O-antigen (Strauss et al, 2009). The O-antigen constitutes the outermost region of
223 LPS, and due to its length of up to 30 nm, likely the first component presented to host cells upon
224 contact (Strauss et al, 2009). These characteristics led us to hypothesize that the O-antigen moiety
225 of EHEC OMVs may initiate their recognition and uptake by host cells.


226
227 In order to investigate this, we compared the uptake kinetics of ClyA-Bla vesicles derived from
228 EHEC O157 wild type cells and the EHEC clinical isolate MA6, which lacks the O157 O-antigen
229 (Rump et al, 2010). While MA6 has an intact *rfb* operon, *gne* was found to have a 1310 bp insertion,
230 preventing synthesis of UPD N-acetyl galactosamine, a substrate required for the first residue of
231 the O-antigen repeating oligosaccharide units (Rush et al, 2010; Rump et al, 2010).
232 Complementation with the *gne* gene from EHEC O157 restored the expression of the O-antigen in
233 EHEC MA6. Despite being isolated from a beef source, MA6 has not been implicated in illness,
234 suggesting a deficiency in its ability to cause infection, despite loss of O-antigen having no effect
235 on growth (Rump et al, 2010). ClyA-Bla reporter OMVs derived from MA6 entered host cells
236 significantly less efficiently than those derived from EHEC wild type cells with intact O-antigen,
237 and overall uptake was decreased by approximately 43% (Figure 4D). The maximum rate of entry
238 of the OMVs from MA6 was not significantly reduced compared with O157 OMVs (Figure 4C).

239

LPS composition determines OMV entry route into host cells | 13

240 In addition, enzymatic removal of LPS O-antigen from EHEC O157 wild type OMVs was used to
241 compare the effect of LPS composition on OMVs uptake kinetics. Cellulase, which possesses endo-
242 1,4-beta-D-glucanase activity, was used to hydrolyze the glycosidic bond between α -L-fucose and
243 β -D-glucose in the repeating unit of the O157 O-antigen (Wang and Reeves, 1998) and efficiently
244 removed the O-antigen from EHEC LPS (Figure S2). Cellulase-treated EHEC reporter OMVs
245 entered host cells significantly slower than those from wild type EHEC, and total uptake efficiency
246 was decreased by approximately 63% (Figure 4C).

247
248 *E. coli* MG1655 has lost its ability to produce O-antigen due to a disruption in *wbbL* encoding the
249 rhamnosyltransferase required for O-antigen synthesis (Liu and Reeves, 1994). In the MG1655 L9
250 strain, wild type *wbbL* has been restored, allowing expression of the strain's original O16 O-antigen
251 (Browning et al, 2013, Figure S2). We carried out FRET assays with HeLa cells exposed to ClyA-
252 Bla reporter OMVs harvested from MG1655 and MG1655 L9 strains, to determine if restoration
253 of its O-antigen would impact OMV uptake kinetics (Figure 4E-H). HeLa cells incubated with
254 reporter OMVs from MG1655 L9 showed a significantly higher total change in FRET signal
255 compared with cells incubated with OMVs from MG1655 (Figure 4A, D). There was no significant
256 difference between the maximum rates of uptake, but the rate of uptake decelerated quicker for the
257 MG1655 than the MG1655 L9 strain (Figure 4B, C), suggesting presence of O16 O-antigen on
258 OMVs causes an increase in efficiency of uptake, but does not affect rate of uptake as much as
259 O157 O-antigen. Taken together, these results suggest that the presence of O-antigen increases the
260 uptake efficiency of OMVs, and depending on the chemical composition of the O-antigen, can
261 enhance the rate of uptake or sustain an elevated uptake rate, compared to LPS lacking O-antigen.



262

263 **Figure 4. The presence and composition of LPS O-antigen on OMVs affects rate and efficiency of vesicle uptake**
 264 **by host cells**

265 (A) CCF2-AM loaded HeLa cells were exposed to ClyA-Bla OMVs isolated from EHEC O157 (red), EHEC MA6
 266 (blue), or EHEC O157 OMVs treated with cellulase (lilac) at an MOI of 1000 for 3 hours. The FRET signal (ratio of
 267 blue:green fluorescence) over time was plotted as mean \pm stdev (n=3).

268 (B) Polynomials were fitted to each data set from (A) using the cubic spline function csaps in Matlab. Numerical
 269 estimates of the gradients of the resulting polynomials were determined using the gradient function and plotted as
 270 means \pm stdev (n=3).

271 (C) Maximum rates were determined from data in (B) to visualize speed of uptake for EHEC O157 (red), EHEC MA6
 272 (blue) or cellulase-treated EHEC O157 OMVs (lilac). Data shown are means \pm stdev (n=3) and significance was
 273 determined using ANOVA (***) indicates $p \leq 0.001$.

274 (D) Total FRET changes after 3 hrs were determined from data in (A) and plotted to visualize overall efficiency of
 275 uptake for EHEC wt (red), EHEC MA6 (blue) or cellulase-treated EHEC wt OMVs (lilac). Data shown are means \pm
 276 stdev (n=3) and significance was determined by ANOVA (**) indicates $p \leq 0.01$, (*) $p \leq 0.05$, ns – no significant
 277 difference ($p \geq 0.05$).

278 (E) CCF2-AM loaded HeLa cells were exposed to ClyA-Bla OMVs isolated from MG1655 L9 (red) or MG1655
 279 (purple) at an MOI of 1000 for 3 hours. The FRET signal (ratio of blue:green fluorescence) over time was plotted as
 280 mean \pm stdev (n=3).

281 (F) Polynomials were fitted to each data set from (E) using the cubic spline function csaps in Matlab. Numerical
 282 estimates of the gradients of the resulting polynomials were determined using the gradient function and plotted as
 283 means \pm stdev (n=3).

284 (G) Maximum rates were determined from data in (F) to visualize speed of uptake for OMVs isolated from MG1655
 285 L9 (red) or MG1655 (purple). Data shown are means \pm stdev (n=3) and significance was determined using student's
 286 t-test. ns-no significant differences.

287 (H) Total FRET changes after 3 hrs were determined from data in (E) and plotted to visualize overall efficiency of
 288 uptake for OMVs isolated from MG1655 L9 (red) or MG1655 (purple). Data shown are means \pm stdev (n=3) and
 289 significance was determined by student's t-test. (*) indicates $p \leq 0.05$.


290 **Macropinocytosis is a minor route of uptake and decreases the efficiency of OMV entry to**
291 **host cells**

292 Macropinocytosis (Kaparakis-Liaskos and Ferrero, 2015), clathrin dependent endocytosis (Parker
293 et al, 2010), and non-clathrin mediated endocytosis via lipid rafts (Thay et al, 2014; Mondal et al,
294 2016) have all been proposed as mechanism of vesicle uptake by host cells. These discrepancies
295 may in part be due to differences in OMV composition, as well as methods used to study uptake
296 (O'Donoghue and Krachler, 2016). We used reporter OMVs to evaluate the relative contribution
297 of cellular trafficking pathways to OMV uptake and determine if these are affected by LPS
298 composition.

299 To evaluate the relative contribution of macropinocytosis, OMV uptake kinetics were studied in
300 untreated cells and compared to HeLa cells treated with 20 uM blebbistatin to inhibit
301 macropinocytosis (Jiang et al, 2010). Inhibition of macropinocytosis slightly enhanced the rate and
302 overall efficiency of uptake, both for EHEC and MG1655 OMVs (Figure 5), suggesting that a small
303 fraction of OMVs usually enters cells by macropinocytosis but that this pathway is not the major
304 route of uptake, and is a slower way of uptake compared to the major route of entry.

305
306 To evaluate whether OMV uptake was dynamin dependent, we compared FRET traces for HeLa
307 cells left untreated or treated with 80 uM dynasore to inhibit dynamin-dependent uptake (Nagasawa
308 et al, 2014) prior to incubation with EHEC or MG1655 OMVs. Dynasore treatment almost
309 completely abolished uptake of both EHEC and MG1655 OMVs (Figure 5), suggesting both
310 species use either receptor-mediated endocytosis or caveolin-mediated endocytosis as their major
311 uptake route.

LPS composition determines OMV entry route into host cells | 16



312

313 **Figure 5. Macropinocytosis is a minor route of uptake and decreases the efficiency of OMV entry to host cells**

314 (A) HeLa cells were either left untreated (red), or pre-treated with 80 μM dynasore (lilac) or 20 μM blebbistatin (violet) and exposed to ClyA-Bla OMVs isolated from EHEC at an MOI of 1000 for 3 hours. The FRET signal (ratio of blue:green fluorescence) over time was plotted as mean ± stdev (n=3).

315 (B) Polynomials were fitted to each data set from (A) using the cubic spline function csaps in Matlab. Numerical estimates of the gradients of the resulting polynomials were determined using the gradient function and plotted as means ± stdev (n=3).

316 (C) Maximum rates were determined from data in (B) to visualize speed of OMV uptake into untreated HeLa cells (red), or cells pre-treated with 80 μM dynasore (lilac) or 20 μM blebbistatin (violet). Data shown are means ± stdev (n=3) and significance was determined using ANOVA (****) indicates p ≤ 0.0001, ns-not significant (p ≥ 0.05).

317 (D) Total FRET changes after 3 hrs were determined from data in (A) and plotted to visualize overall efficiency of uptake into untreated HeLa cells (red), or cells pre-treated with 80 μM dynasore (lilac) or 20 μM blebbistatin (violet). Data shown are means ± stdev (n=3) and significance was determined by ANOVA (***) indicates p ≤ 0.001, (***)p ≤ 0.01.

327 (E) HeLa cells were either left untreated (red), or pre-treated with 80 μM dynasore (lilac) or 20 μM blebbistatin (violet) and exposed to ClyA-Bla OMVs isolated from MG1655 at an MOI of 1000 for 3 hours. The FRET signal (ratio of blue:green fluorescence) over time was plotted as mean ± stdev (n=3).

328 (F) Polynomials were fitted to each data set from (E) using the cubic spline function csaps in Matlab. Numerical estimates of the gradients of the resulting polynomials were determined using the gradient function and plotted as means ± stdev (n=3).

329 (G) Maximum rates were determined from data in (F) to visualize speed of MG1655 OMV uptake into untreated HeLa cells (red), or cells pre-treated with 80 μM dynasore (lilac) or 20 μM blebbistatin (violet). Data shown are means ± stdev (n=3) and significance was determined using ANOVA (***) indicates p ≤ 0.001.

330 (H) Total FRET changes after 3 hrs were determined from data in (E) and plotted to visualize overall efficiency of MG1655 OMV uptake into untreated HeLa cells (red), or cells pre-treated with 80 μM dynasore (lilac) or 20 μM blebbistatin (violet). Data shown are means ± stdev (n=3) and significance was determined by ANOVA (***) indicates p ≤ 0.001, (***) p ≤ 0.01.

339

340 **Chemical composition of LPS determines the preferred route of vesicular uptake by host cells**

341 Since our previous experiments had revealed entry of OMVs into host cells was dynamin -
342 dependent, we next sought to determine whether the entry of OMVs was dependent on clathrin-
343 mediated endocytosis, which utilises protein receptors on the host cell surface, or lipid raft-
344 mediated endocytosis, both of which require dynamin (Vercauteren et al, 2010, Chatterjee and
345 Chaudhuri, 2011; Mulcahy et al, 2014). To inhibit clathrin-mediated endocytosis, protein receptors
346 on host cells were removed by treatment with 5 µg/ml papain prior to incubation with EHEC,
347 MG1655 or MG1655 L9 OMVs. Removal of protein receptors from the host surface led to a
348 marked increase in both rate and efficiency of uptake for EHEC and MG1655 L9 OMVs, but
349 abolished uptake of MG1655 OMVs (Figure 6A-L). Pre-treatment of host cells with 1 µg/ml
350 chlorpromazine, which disrupts the formation of clathrin-coated pits (Wang, Rothberg and
351 Anderson, 1993), had a similar effect to papain treatment, and increased rate and efficiency of
352 uptake for EHEC and MG1655 L9, but not for MG1655 OMVs (Figure 6). This indicates that
353 OMVs from MG1655, which lack O-antigen, depend on receptor-mediated endocytosis to enter
354 host cells, whereas EHEC and MG166 L9 OMVs, which feature intact O-antigen, are able to utilize
355 receptor-independent pathways as their major route of entry. While a small fraction of EHEC
356 vesicles appears to enter cells via receptor-mediated endocytosis, inhibition of this route actually
357 increases their uptake rate and efficiency.


358

359 **OMVs from EHEC preferentially use lipid raft mediated endocytosis to enter host cells**

360 Since entry of OMVs containing intact O-antigen seemed to be receptor-independent, we
361 investigated whether these OMVs required lipid rafts to enter host cells. Lipid raft-mediated
362 endocytosis was inhibited using 5 mM methyl-β-cyclodextrin treatment to sequester cholesterol

363 from host cell membranes. Alternatively, cells were treated with 1 μ g/ml filipin to disrupt the
364 dynamics of cholesterol-rich microdomains (Nagasawa et al, 2014) prior to incubation with
365 reporter OMVs. Disruption of cholesterol-rich microdomains via both methods led to a marked
366 reduction in rate and efficiency of OMV uptake, and this reduction was most pronounced for EHEC
367 OMVs. Filipin in particular almost completely abolished the uptake of EHEC OMVs (Figure 6A-
368 D). Lipid raft domains can also contain caveolins, which coat cave-like invaginations in the plasma
369 membrane and result in internalization of contents in a process that is also dynamin-dependent
370 (Rewatkar et al, 2015). Since our previous experiments demonstrated the requirement of dynamin
371 for OMV entry (Figure 5), we conclude lipid-raft dependent, caveolin-mediated endocytosis is the
372 major route of entry for EHEC OMVs.

LPS composition determines OMV entry route into host cells | 19



374 **Figure 6. OMVs lacking O-antigen rely on receptor-mediated endocytosis, while OMVs featuring O-antigen**
375 **preferentially enter host cells via lipid rafts**

376 (A) HeLa cells were either left untreated (red), or pre-treated with 5 ug/ml papain (lilac), 1 ug/ml chlorpromazine
377 (purple), 5mM methyl-b cyclodextrin (maroon) or 1µg/ml filipin (orange) and exposed to ClyA-Bla OMVs isolated
378 from EHEC at an MOI of 1000 for 3 hours. The FRET signal (ratio of blue:green fluorescence) over time was plotted
379 as mean ± stdev (n=3).

380 (B) Polynomials were fitted to each data set from (A) using the cubic spline function csaps in Matlab. Numerical
381 estimates of the gradients of the resulting polynomials were determined using the gradient function and plotted as
382 means ± stdev (n=3).

383 (C) Maximum rates were determined from data in (B) to visualize speed of OMV uptake into untreated HeLa cells
384 (red), or cells pre-treated with 5 ug/ml papain (lilac), 1 ug/ml chlorpromazine (purple), 5mM methyl-b cyclodextrin
385 (maroon) or 1µg/ml filipin (orange). Data shown are means ± stdev (n=3) and significance was determined using
386 ANOVA (** indicates $p \leq 0.01$, ns-not significant ($p \geq 0.05$)).

387 (D) Total FRET changes after 3 hrs were determined from data in (A) and plotted to visualize overall efficiency of
388 uptake into untreated HeLa cells (red), or cells pre-treated with 5 ug/ml papain (lilac), 1 ug/ml chlorpromazine (purple),
389 5mM methyl-b cyclodextrin (maroon) or 1µg/ml filipin (orange). Data shown are means ± stdev (n=3) and significance
390 was determined by ANOVA (***) indicates $p \leq 0.001$, (**) $p \leq 0.01$.

391 (E) HeLa cells were either left untreated (red), or pre-treated with 5 ug/ml papain (lilac), 1 ug/ml chlorpromazine
392 (purple), 5mM methyl-b cyclodextrin (maroon) or 1µg/ml filipin (orange) and exposed to ClyA-Bla OMVs isolated
393 from MG1655 at an MOI of 1000 for 3 hours. The FRET signal (ratio of blue:green fluorescence) over time was plotted
394 as mean ± stdev (n=3).

395 (F) Polynomials were fitted to each data set from (E) using the cubic spline function csaps in Matlab. Numerical
396 estimates of the gradients of the resulting polynomials were determined using the gradient function and plotted as
397 means ± stdev (n=3).

398 (G) Maximum rates were determined from data in (F) to visualize speed of MG1655 OMV uptake into untreated HeLa
399 cells (red), or cells pre-treated with 5 ug/ml papain (lilac), 1 ug/ml chlorpromazine (purple), 5mM methyl-b
400 cyclodextrin (maroon) or 1µg/ml filipin (orange). Data shown are means ± stdev (n=3) and significance was determined
401 using ANOVA (***) indicates $p \leq 0.001$, (*) $p \leq 0.05$, ns-not significant ($p \geq 0.05$)).

402 (H) Total FRET changes after 3 hrs were determined from data in (E) and plotted to visualize overall efficiency of
403 MG1655 OMV uptake into untreated HeLa cells (red), or cells pre-treated with 5 ug/ml papain (lilac), 1 ug/ml
404 chlorpromazine (purple), 5mM methyl-b cyclodextrin (maroon) or 1µg/ml filipin (orange). Data shown are means ±
405 stdev (n=3) and significance was determined by ANOVA (****) indicates $p \leq 0.0001$, (**) $p \leq 0.01$.

406 (I) HeLa cells were either left untreated (red), or pre-treated with 5 ug/ml papain (lilac), 1 ug/ml chlorpromazine
407 (purple), 5mM methyl-b cyclodextrin (maroon) or 1µg/ml filipin (orange) and exposed to ClyA-Bla OMVs isolated
408 from MG1655 L9 at an MOI of 1000 for 3 hours. The FRET signal (ratio of blue:green fluorescence) over time was
409 plotted as mean ± stdev (n=3).

410 (J) Polynomials were fitted to each data set from (I) using the cubic spline function csaps in Matlab. Numerical
411 estimates of the gradients of the resulting polynomials were determined using the gradient function and plotted as
412 means ± stdev (n=3).

413 (K) Maximum rates were determined from data in (J) to visualize speed of MG1655 L9 OMV uptake into untreated
414 HeLa cells (red), or cells pre-treated with 5 ug/ml papain (lilac), 1 ug/ml chlorpromazine (purple), 5mM methyl-b
415 cyclodextrin (maroon) or 1µg/ml filipin (orange). Data shown are means ± stdev (n=3) and significance was determined
416 using ANOVA (****) indicates $p \leq 0.0001$, (*) $p \leq 0.05$, ns-not significant ($p \geq 0.05$)).

417 (L) Total FRET changes after 3 hrs were determined from data in (I) and plotted to visualize overall efficiency of
418 MG1655 L9 OMV uptake into untreated HeLa cells (red), or cells pre-treated with 5 ug/ml papain (lilac), 1 ug/ml
419 chlorpromazine (purple), 5mM methyl-b cyclodextrin (maroon) or 1µg/ml filipin (orange). Data shown are means ±
420 stdev (n=3) and significance was determined by ANOVA (***) indicates $p \leq 0.001$, (**) $p \leq 0.01$.

421

422

423 **Purified LPS competes with EHEC OMVs for caveolin mediated endocytosis**

424 Finally, we considered whether purified LPS would competitively inhibit OMV uptake into host
425 cells. Prior to infection with OMVs, HeLa cells were pre-incubated with 1 µg/ml LPS from either
426 smooth or rough strains (i.e, with or without O-antigen). Supplementation with LPS strongly
427 decreased the rate of uptake of EHEC OMVs, but had no significant effect on uptake of OMVs
428 from MG1655 or L9 (Figure S3). LPS is known to associate with the host TLR4 receptor, but
429 inhibition of TLR4 by pre-treatment of cells with C34 (Neal et al, 2013) did not inhibit uptake of
430 OMVs, suggesting that they are not competing for TLR4 (Figure S4). TLR4 activation also requires
431 CD14 binding, a protein localised in cholesterol rich lipid raft domains (Plociennikowska et al,
432 2015). We demonstrated that entry of EHEC OMVs is strongly dependent on cholesterol-rich
433 regions of the membrane and we suggest that purified LPS, by recruiting TLR4 signaling
434 complexes in cholesterol-rich regions of the membrane, competes with OMVs for binding in these
435 domains, resulting in a reduction in vesicular uptake.

436

437

438 **DISCUSSION**

439 Interactions between bacterial outer membrane vesicles and epithelial cells are now recognized as
440 an important driver of bacterial pathogenesis, and play key roles in toxin delivery, modulation of
441 mucosal immune responses and immune priming. Yet, our ability to study vesicle-host cell
442 interactions and dissect bacterial and host factors determining route of uptake and thus, the fate of
443 vesicular cargo within the host, has been limited by a lack of methods to study vesicle entry and
444 cargo release in real-time and without altering the physicochemical properties of the vesicle. Here
445 we describe a novel assay that fulfils these requirements and allowed us to study the kinetics of
446 OMV uptake with enough temporal resolution to reveal critical differences between rate and uptake
447 efficiency of vesicles derived from pathogenic and non-pathogenic strains. The assay is sensitive
448 enough to register nuanced differences in the kinetics of OMVs decorated with O-antigens of
449 different chemical composition. Current methods for studying the mechanisms of OMV-mediated
450 delivery of bacterial cargo into host cells have produced inconsistent and often contradictory
451 findings, often relying on less quantitative approaches, such as membrane labelling and
452 immunofluorescence, or using changes in cytotoxicity or host cell phenotype as an indicator of
453 OMV cargo delivery. The method presented here provides a consistent platform to further study
454 the pathways involved and measure the kinetics of OMV entry into host cells by utilising a
455 sensitive, adaptable and quantifiable approach that can easily be adapted to a high-throughput
456 format, and potentially to study OMV-host interactions *in vivo* (Raz et al, 1998).

457 We selected EHEC as a proof-of-concept species here, since EHEC OMVs have been shown to
458 play a crucial role in toxin stabilization and delivery (Aldick et al, 2008), and have been considered
459 as a means to vaccinate and protect against hemolytic uremic syndrome, a severe complication of

460 EHEC infection (Choi et al, 2014). However, we expect the genetically encoded ClyA-Bla reporter
461 would similarly be targeted to other Gram-negative species of interest, and this will be subject of
462 further investigation to clarify if the herein identified surface features are equally important
463 determinants in driving uptake of OMVs from other species.

464 Our experiments demonstrated that OMVs from EHEC O157, a successful pathogenic strain of *E.*
465 *coli*, enter host cells more rapidly and efficiently than those from the lab strain *E. coli* MG1655
466 (Figure 3). OMVs are able to transport a wide variety of cargo molecules from the bacterial cell
467 into its external environment, and thus the roles that OMVs have in enhancing bacterial fitness are
468 equally diverse (Kuehn and Kesty, 2005; Haurat et al, 2015). This data suggests that pathogens
469 such as EHEC may have fine-tuned their cell wall composition in accordance with the role of
470 OMVs for delivery of virulence factors, such as hemolysins and shiga-like toxins, into the host
471 during infection (Horstmann and Kuehn, 2000; Manning and Kuehn, 2011; Bielaszewska et al,
472 2013).

473 Whilst there are many genes that are likely to contribute to the pathogenesis of EHEC, with 1632
474 proteins present that are absent in MG1655, a significant component of OMVs is LPS, a structure
475 unique to Gram-negative bacteria (Hayashi et al, 2001). Recent work showed that EHEC OMVs
476 allow efficient delivery of LPS into the host cell cytoplasm, resulting in inflammatory responses,
477 caspase-11 activation and cell death (Kunsmann et al, 2015; Vanaja et al, 2016). LPS is composed
478 of the well conserved Lipid A, which forms the outer leaflet of the lipid bilayer and is attached to
479 the core oligosaccharide regions, and in ‘smooth’ strains the core is linked to a highly variable,
480 repetitive polysaccharide region known as O-antigen (Park et al, 2009; Strauss et al, 2009). O-
481 antigen is found at the outer-most portion of the LPS and although variable in length, can consist

482 of up to 100 repeating units and protrude over 30 nm from the membrane (Strauss et al, 2009). The
483 presence of O-antigen can provide several fitness advantages, such as enhancing resistance to
484 complement, phagocytosis and phage infection (Liang-Takasaki et al, 1982; Van der Ley et al,
485 1986). Pathogenic strains are often ‘smooth’, and the O-antigen can increase bacterial virulence,
486 with the length of the O-antigen positively correlated with the ability of the bacterial cell to adhere
487 to host cells and tissues, while loss of O-antigen results in defects in colonisation, biofilm
488 formation, and increased clearance of infection (Sheng et al, 2008; Strauss et al, 2009; Hathroubi
489 et al, 2016). The importance of O-antigen for adhesion to host epithelial cells has been previously
490 demonstrated in studies using *H. pylori*, but had not been explored in the context of OMVs
491 (Edwards et al, 2000). The position of the O-antigen at the outer surface of the OMV means it may
492 be of relevance for establishing initial contact and facilitating adhesion and entry.

493 MG1655 is a ‘rough’ strain that has undergone a mutation in the *wbbL* gene of the *rfb* cluster,
494 causing loss of its native O16 O-antigen (Liu and Reeves, 1994). When synthesis of the O16
495 antigen was restored to generate MG1655 L9, it was able to colonize the intestine of
496 *Caenorhabditis elegans* and cause disease, suggesting that the O-antigen is a requirement for
497 pathogenesis (Browning et al, 2013). In addition, loss of the EHEC O157 antigen results in reduced
498 virulence of the strain in an animal model (Miyashita et al, 2012). In our experiments, OMVs from
499 EHEC MA6, which lacks the O-antigen, entered host cells significantly less efficiently than OMVs
500 from wild type EHEC. This was also observed when the O-antigen subunits were enzymatically
501 cleaved using a glycoside hydrolase. The presence of O16 antigen for MG1655 L9 OMVs did not
502 significantly affect the maximum rate of uptake, but did significantly increase the overall efficiency
503 of uptake compared to MG1655 OMVs by sustaining a higher uptake rate for longer. These

504 differences we observed between O157 and O16 antigens suggest the chemical composition and
505 length of the O-antigen may have a role in fine-tuning entry kinetics and fate of cargo post-uptake.
506 The sugar composition of the O-antigen is highly variable, as is the number of repeating units
507 (Franco, Liu and Reeves, 1998). The O-antigen of most *E. coli* strains has 10-18 repeats, whilst
508 EHEC O157 can exceed 80 repeats (Franco, Liu and Reeves, 1998; Kalynych et al, 2011). The
509 length of the O-antigen in EHEC can be over 30 nm, and the number of repeating units has been
510 previously positively correlated with virulence (Murray, Attridge and Morona, 2006; Strauss et al
511 2009).

512 We used our newly-devised assay to identify the relative contributions of cellular uptake pathways
513 to OMV entry into host cells. Inhibition of clathrin-mediated endocytosis by treatment of cells with
514 papain resulted in a significantly increased rate of uptake for EHEC, but a significant reduction in
515 entry for OMVs from MG1655. For OMVs from MG1655 L9, there was no change in rate but an
516 increased total uptake, suggesting a change in the OMV entry phenotype in the presence of O-
517 antigen. This indicates that OMVs without O-antigen rely on protein receptors and clathrin-
518 mediated endocytosis in order to gain access to the host cell, whilst OMVs with O-antigen are not
519 inhibited by the loss of this pathway. We propose that the presence of the O-antigen may lead to
520 possible ligands in the inner regions of the LPS being obscured, whereas these potential receptor
521 binding regions are exposed in the absence of O-antigen, and interestingly, loss of the receptor-
522 mediated pathway is beneficial to EHEC, and this may be due to a preference for the non-receptor
523 mediated pathways which allow for more efficient cargo delivery from OMVs.

524 When lipid raft mediated endocytosis was inhibited, total uptake of OMVs from all three strains
525 was reduced, but the relative decrease in efficiency was largest for EHEC OMVs, which also


526 showed a significant decrease in the rate of uptake (Figure 6). This indicated that in contrast to
527 MG1655, EHEC OMVs preferentially utilize clathrin-independent entry routes. Entry was also
528 dynamin-dependent, suggesting OMVs containing O-antigen are taken up by caveolin-mediated
529 endocytosis. OMVs from EHEC contribute to infection via delivery of diverse virulence factors,
530 and this may be a further adaptation to pathogenesis for EHEC, as although the rate of
531 internalization by caveolae is around 5 times slower than that of clathrin-dependent endocytosis,
532 unlike clathrin-coated pits caveolae do not enter endocytic trafficking routes, and thus are not
533 targeted to lysosomes for processing or degradation (Ritter et al, 1995; Bielaszewska et al, 2013).
534 Instead, the contents of caveolae rapidly diffuse into the cytoplasm, consistent with our observation
535 of a rapid increase in cytoplasmic dye cleavage and thus, rapid decrease in FRET almost
536 immediately after vesicle addition to cells. These findings underpin the notion that internalization
537 via caveolin-mediated endocytosis allows more efficient delivery of cargo into host cells (Ritter et
538 al, 1995). When clathrin-mediated endocytosis is inhibited, it becomes obligatory for OMVs to
539 utilize the more efficient caveolin pathway, which would explain the increased total change in blue
540 fluorescence observed for EHEC OMVs when cells are treated with papain or chlorpromazine. It
541 may be that OMVs from MG1655 lacking O-antigen are less well adapted to using this route, and
542 the presence of the O-antigen on OMVs from MG1655 L9 enhances their ability to use the
543 alternative caveolin-mediated route of entry (Figure 7).

544 Previous work with *H. pylori* OMVs had indicated an inhibitory role of extracellular LPS on OMV
545 uptake (Parker et al, 2010). In our experiments, we found that addition of purified LPS resulted in
546 significant inhibition of uptake of EHEC OMVs, but had no effect on uptake of OMVs from
547 MG1655 or L9. LPS is recognized by the TLR4 receptor on the host cell membrane, but activation

548 of this receptor requires binding of LPS to the CD14 protein which is associated with lipid raft
549 microdomains and caveolae (Shuto et al, 2005; Plociennikowska et al, 2015). EHEC OMVs were
550 strongly dependent on lipid rafts for their entry, and were most affected by inhibition of this
551 pathway with cholesterol sequestering agents (Figure 6). Inhibition of TLR4 using C34, a small
552 molecule which competitively binds the TLR4-MD2 complex, had no significant effect on uptake
553 of OMVs (Figure S4) (Neal et al, 2013). In addition, we showed that removal of surface receptors
554 resulted in an increased rate of uptake for EHEC OMVs, suggesting they are not dependent on
555 receptor-mediated endocytosis (Figure 6). We conclude that EHEC OMVs are competing with
556 purified LPS for cholesterol-rich domains of the cell membrane required both for the formation of
557 TLR4 signaling complexes and vesicular uptake, rather than directly competing for the TLR4
558 receptor.

559

LPS composition determines OMV entry route into host cells | 28



560

561 **Figure 7. LPS composition determines major route and kinetics of OMV entry into host cells.**

562

563

564 Whilst it is well established that pathogenic species utilize OMVs during infection, the specific

565 adaptations which allow OMVs to contribute to pathogenesis require further exploration. This work

566 has developed a new approach to overcome current methodological limitations and provide

567 consistent data for future studies and allow new insights into the interactions of OMVs with host

568 cells during infection. Our data demonstrate the relevance of LPS composition, in particular the

569 presence and chemical composition of O-antigen, in shaping route and entry kinetics of OMVs.

570 Further work in this area may reveal targets for inhibition of these processes, and enable attenuation

571 of infections by preventing the OMV-associated delivery of virulence factors.

572

573

574 **AUTHOR CONTRIBUTIONS**

575 E.J.O, D.B., L.J.A. and A.M.K. designed experiments, D.B. and L.J.A contributed reagents, E.J.O.
576 and E.B. performed experiments, E.J.O., E.B., S.J. and A.M.K. analyzed data, E.B. performed
577 electron microscopy, and E.J.O., S.J. and A.M.K. contributed to writing the manuscript. All authors
578 checked and approved the final version of the manuscript.

579

580 **ACKNOWLEDGMENTS**

581 We thank Matthew DeLisa (Cornell Univ.) for providing ClyA-Bla and Bla-ClyA plasmid
582 constructs and Peter Feng (FDA, Maryland) for providing the EHEC MA6 strain. We thank staff
583 at the Birmingham Electron Microscopy Facility for technical help with sample preparation and
584 transmission electron microscopy. We thank members of the Krachler lab for critical reading and
585 comments on the manuscript. This work was supported by BBSRC grants BB/M021513/1 and
586 BB/L007916/1 (to A.M.K.), and a BBSRC MIBTP studentship (to E.J.O).

587

588 **REFERENCES**

- 589 Alaniz, R.C., Deatherage, B.L., Lara, J.C. & Cookson, B.T. (2007) Membrane Vesicles Are
590 Immunogenic Facsimiles of Salmonella typhimurium That Potently Activate Dendritic Cells, Prime
591 B and T Cell Responses, and Stimulate Protective Immunity In Vivo. *The Journal of Immunology*,
592 179, 7692-7701.
- 593
594 Aldick, T., Bielaszewska, M., Uhlin, B.E., Humpf, H.U., Wai, S.N. & Karch, H. (2009) Vesicular
595 stabilization and activity augmentation of enterohaemorrhagic *Escherichia coli* haemolysin. *Mol*
596 *Microbiol*, 71, 1496-1508.
- 597
598 Bauman, S.J. & Kuehn, M.J. (2009) *Pseudomonas aeruginosa* vesicles associate with and are
599 internalized by human lung epithelial cells. *BMC Microbiol*, 9, 26.
- 600
601 Berleman, J. & Auer, M. (2013) The role of bacterial outer membrane vesicles for intra- and
602 interspecies delivery. *Environ Microbiol*, 15, 347-354.
- 603
604 Bielaszewska, M., Ruter, C., Kunsmann, L., Greune, L., Bauwens, A., Zhang, W., Karch, H. (2013)
605 Enterohemorrhagic *Escherichia coli* hemolysin employs outer membrane vesicles to target
606 mitochondria and cause endothelial and epithelial apoptosis. *PLoS Pathog*, 9, e1003797.
- 607
608 Bomberger, J.M., Maceachran, D.P., Coutermarsh, B.A., Ye, S., O'Toole, G.A. & Stanton, B.A.
609 (2009) Long-distance delivery of bacterial virulence factors by *Pseudomonas aeruginosa* outer
610 membrane vesicles. *PLoS Pathog*, 5, e1000382.
- 611 Bonnington, K.E. & Kuehn, M.J. (2014) Protein selection and export via outer membrane vesicles.
612 *Biochim Biophys Acta*, 1843, 1612-1619.
- 613
614 Browning, D.F., Wells, T.J., Franca, F.L., Morris, F.C., Sevastyanovich, Y.R., Bryant,
615 J.A., Henderson, I.R. (2013) Laboratory adapted *Escherichia coli* K-12 becomes a pathogen of
616 *Caenorhabditis elegans* upon restoration of O antigen biosynthesis. *Mol Microbiol*, 87, 939-950.
- 617
618 Cahill, B.K., Seeley, K.W., Gutel, D. & Ellis, T.N. (2015) *Klebsiella pneumoniae* O antigen loss
619 alters the outer membrane protein composition and the selective packaging of proteins into secreted
620 outer membrane vesicles. *Microbiol Res*, 180, 1-10.
- 621
622 Chatterjee, D. & Chaudhuri, K. (2011) Association of cholera toxin with *Vibrio cholerae* outer
623 membrane vesicles which are internalized by human intestinal epithelial cells. *FEBS Lett*, 585,
624 1357-1362.
- 625
626 Choi, K.S., Kim, S.H., Kim, E.D., Lee, S.H., Han, S.J., Yoon, S., Seo, K.Y. (2014) Protection from
627 hemolytic uremic syndrome by eyedrop vaccination with modified enterohemorrhagic *E. coli* outer
628 membrane vesicles. *PLoS One*, 9, e100229.
- 629
630 Edwards, N.J., Monteiro, M.A., Faller, G., Walsh, E.J., Moran, A.P., Roberts, I.S., High, N.J. (2000)
631 Lewis X structures in the O antigen side-chain promote adhesion of *Helicobacter pylori* to the
632 gastric epithelium. *Mol Microbiol*, 35, 1530-1539.
- 633
634 Franco, A.V., Liu, D. & Reeves, P.R. (1998) The wzz (cld) protein in *Escherichia coli*: amino acid
635 sequence variation determines O-antigen chain length specificity. *J Bacteriol*, 180, 2670-2675.

- 636
637 Gujrati, V., Kim, S., Kim, S.H., Min, J.J., Choy, H.E., Kim, S.C.Jon, S. (2014) Bioengineered
638 bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS
639 Nano, 8, 1525-1537.
640
641 Hathroubi, S., Hancock, M.A., Bosse, J.T., Langford, P.R., Tremblay, Y.D., Labrie, J.Jacques, M.
642 (2016) Surface Polysaccharide Mutants Reveal that Absence of O Antigen Reduces Biofilm
643 Formation of *Actinobacillus pleuropneumoniae*. *Infect Immun*, 84, 127-137.
644
645 Haurat, M.F., Elhenawy, W. & Feldman, M.F. (2015) Prokaryotic membrane vesicles: new insights
646 on biogenesis and biological roles. *Biol Chem*, 396, 95-109.
647
648 Hayashi, T., Makino, K., Ohnishi, M., Kurokawa, K., Ishii, K., Yokoyama, K., Shinagawa, H. (2001)
649 Complete genome sequence of enterohemorrhagic *Escherichia coli* O157:H7 and genomic
650 comparison with a laboratory strain K-12. *DNA Res*, 8, 11-22.
651
652 Horstman, A.L. & Kuehn, M.J. (2000) Enterotoxigenic *Escherichia coli* secretes active heat-labile
653 enterotoxin via outer membrane vesicles. *J Biol Chem*, 275, 12489-12496.
654
655 Jiang, J., Kolpak, A.L. & Bao, Z.Z. (2010) Myosin IIB isoform plays an essential role in the
656 formation of two distinct types of macropinosomes. *Cytoskeleton (Hoboken)*, 67, 32-42.
657 Kalynych, S., Ruan, X., Valvano, M.A. & Cygler, M. (2011) Structure-guided investigation of
658 lipopolysaccharide O-antigen chain length regulators reveals regions critical for modal length
659 control. *J Bacteriol*, 193, 3710-3721.
660
661 Kaparakis, M., Turnbull, L., Carneiro, L., Firth, S., Coleman, H.A., Parkington, H.C.Ferrero, R.L.
662 (2010) Bacterial membrane vesicles deliver peptidoglycan to NOD1 in epithelial cells. *Cell*
663 *Microbiol*, 12, 372-385.
664
665 Kim, J.Y., Doody, A.M., Chen, D.J., Cremona, G.H., Shuler, M.L., Putnam, D.DeLisa, M.P. (2008)
666 Engineered bacterial outer membrane vesicles with enhanced functionality. *J Mol Biol*, 380, 51-66.
667
668 Kuehn, M.J. & Kesty, N.C. (2005) Bacterial outer membrane vesicles and the host-pathogen
669 interaction. *Genes Dev*, 19, 2645-2655.
670
671 Kulp, A. & Kuehn, M.J. (2010) Biological functions and biogenesis of secreted bacterial outer
672 membrane vesicles. *Annu Rev Microbiol*, 64, 163-184.
673
674 Kunsmann, L., Ruter, C., Bauwens, A., Greune, L., Gluder, M., Kemper, B.Bielaszewska, M.
675 (2015) Virulence from vesicles: Novel mechanisms of host cell injury by *Escherichia coli* O104:H4
676 outbreak strain. *Sci Rep*, 5, 13252.
677
678 Liang-Takasaki, C.J., Makela, P.H. & Leive, L. (1982) Phagocytosis of bacteria by macrophages:
679 changing the carbohydrate of lipopolysaccharide alters interaction with complement and
680 macrophages. *J Immunol*, 128, 1229-1235.
681
682 Lindmark, B., Rompikuntal, P.K., Vaitkevicius, K., Song, T., Mizunoe, Y., Uhlin, B.E.Wai, S.N.
683 (2009) Outer membrane vesicle-mediated release of cytolethal distending toxin (CDT) from
684 *Campylobacter jejuni*. *BMC Microbiol*, 9, 220.

- 685
686 Liu, D. & Reeves, P.R. (1994) *Escherichia coli* K12 regains its O antigen. *Microbiology*, 140, 49-
687 57.
688
- 689 Lulevich, V., Shih, Y.P., Lo, S.H. & Liu, G.Y. (2009) Cell tracing dyes significantly change single
690 cell mechanics. *J Phys Chem B*, 113, 6511-6519.
691
- 692 MacDonald, I.A. & Kuehn, M.J. (2012) Offense and defense: microbial membrane vesicles play
693 both ways. *Res Microbiol*, 163, 607-618.
694
- 695 Manning, A.J. & Kuehn, M.J. (2011) Contribution of bacterial outer membrane vesicles to innate
696 bacterial defense. *BMC Microbiol*, 11, 258.
697
- 698 Miyashita, A., Iyoda, S., Ishii, K., Hamamoto, H., Sekimizu, K. & Kaito, C. (2012)
699 Lipopolysaccharide O-antigen of enterohemorrhagic *Escherichia coli* O157:H7 is required for
700 killing both insects and mammals. *FEMS Microbiol Lett*, 333, 59-68.
701
- 702 Mondal, A., Tapader, R., Chatterjee, N.S., Ghosh, A., Sinha, R., Koley, H.Pal, A. (2016) Cytotoxic
703 and Inflammatory Responses Induced by Outer Membrane Vesicle-Associated Biologically Active
704 Proteases from *Vibrio cholerae*. *Infect Immun*, 84, 1478-1490.
705
- 705 Mulcahy, L.A., Pink, R.C. & Carter, D.R. (2014) Routes and mechanisms of extracellular vesicle
706 uptake. *J Extracell Vesicles*, 3, 24641.
707
- 708 Murray, G.L., Attridge, S.R. & Morona, R. (2006) Altering the length of the lipopolysaccharide O
709 antigen has an impact on the interaction of *Salmonella enterica* serovar Typhimurium with
710 macrophages and complement. *J Bacteriol*, 188, 2735-2739.
711
- 712 Nagasawa, S., Ogura, K., Tsutsuki, H., Saitoh, H., Moss, J., Iwase, H. Yahiro, K. (2014) Uptake of
713 Shiga-toxigenic *Escherichia coli* SubAB by HeLa cells requires an actin- and lipid raft-dependent
714 pathway. *Cell Microbiol*, 16, 1582-1601.
715
- 716 Neal, M.D., Jia, H., Eyer, B., Good, M., Guerriero, C.J., Sodhi, C.P. Hackam, D.J. (2013) Discovery
717 and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors. *PLoS One*,
718 8, e65779.
719
- 720 O'Donoghue, E.J. & Krachler, A.M. (2016) Mechanisms of outer membrane vesicle entry into host
721 cells. *Cell Microbiol*, doi: 10.1111/cmi.12655.
722
- 723 Oster, P., O'Hallahan, J., Aaberge, I., Tilman, S., Ypma, E. & Martin, D. (2007) Immunogenicity
724 and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
725 *Vaccine*, 25, 3075-3079.
726
- 727 Park, B.S., Song, D.H., Kim, H.M., Choi, B.S., Lee, H. & Lee, J.O. (2009) The structural basis of
728 lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature*, 458, 1191-1195.
729
- 730 Park, K.S., Choi, K.H., Kim, Y.S., Hong, B.S., Kim, O.Y., Kim, J.H. Gho, Y.S. (2010) Outer
731 membrane vesicles derived from *Escherichia coli* induce systemic inflammatory response
732 syndrome. *PLoS One*, 5, e11334.
733

- 734 Parker, H., Chitcholtan, K., Hampton, M.B. & Keenan, J.I. (2010) Uptake of *Helicobacter pylori*
735 outer membrane vesicles by gastric epithelial cells. *Infect Immun*, 78, 5054-5061.
736
- 737 Plociennikowska, A., Hromada-Judycka, A., Borzecka, K. & Kwiatkowska, K. (2015) Co-operation
738 of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. *Cell Mol Life Sci*, 72, 557-
739 581.
740
- 741 Raz, E., Zlokarnik, G., Tsien, R.Y. & Driever, W. (1998) beta-lactamase as a marker for gene
742 expression in live zebrafish embryos. *Dev Biol*, 203, 290-294.
743
- 744 Renelli, M., Matias, V., Lo, R.Y. & Beveridge, T.J. (2004) DNA-containing membrane vesicles of
745 *Pseudomonas aeruginosa* PAO1 and their genetic transformation potential. *Microbiology*, 150,
746 2161-2169.
747
- 748 Rewatkar, P.V., Parton, R.G., Parekh, H.S. & Parat, M.O. (2015) Are caveolae a cellular entry route
749 for non-viral therapeutic delivery systems? *Adv Drug Deliv Rev*, 91, 92-108.
750
- 751 Ritter, T.E., Fajardo, O., Matsue, H., Anderson, R.G. & Lacey, S.W. (1995) Folate receptors
752 targeted to clathrin-coated pits cannot regulate vitamin uptake. *Proc Natl Acad Sci U S A*, 92, 3824-
753 3828.
754
- 755 Roy, K., Hamilton, D.J., Munson, G.P. & Fleckenstein, J.M. (2011) Outer membrane vesicles
756 induce immune responses to virulence proteins and protect against colonization by enterotoxigenic
757 *Escherichia coli*. *Clin Vaccine Immunol*, 18, 1803-1808.
758
- 759 Rump, L.V., Feng, P.C., Fischer, M. & Monday, S.R. (2010) Genetic analysis for the lack of
760 expression of the O157 antigen in an O Rough:H7 *Escherichia coli* strain. *Appl Environ Microbiol*,
761 76, 945-947.
762
- 763 Rush, J.S., Alaimo, C., Robbiani, R., Wacker, M. & Waechter, C.J. (2010) A novel epimerase that
764 converts GlcNAc-P-P-undecaprenol to GalNAc-P-P-undecaprenol in *Escherichia coli* O157. *J Biol*
765 *Chem*, 285, 1671-1680.
766
- 767 Sheng, H., Lim, J.Y., Watkins, M.K., Minnich, S.A. & Hovde, C.J. (2008) Characterization of an
768 *Escherichia coli* O157:H7 O-antigen deletion mutant and effect of the deletion on bacterial
769 persistence in the mouse intestine and colonization at the bovine terminal rectal mucosa. *Appl*
770 *Environ Microbiol*, 74, 5015-5022.
771
- 772 Shuto, T., Kato, K., Mori, Y., Viriyakosol, S., Oba, M., Furuta, T.Kai, H. (2005) Membrane-
773 anchored CD14 is required for LPS-induced TLR4 endocytosis in TLR4/MD-2/CD14
774 overexpressing CHO cells. *Biochem Biophys Res Commun*, 338, 1402-1409.
775
- 776 Strauss, J., Burnham, N.A. & Camesano, T.A. (2009) Atomic force microscopy study of the role of
777 LPS O-antigen on adhesion of *E. coli*. *J Mol Recognit*, 22, 347-355.
778
- 779 Thay, B., Damm, A., Kufer, T.A., Wai, S.N. & Oscarsson, J. (2014) *Aggregatibacter*
780 *actinomycetemcomitans* outer membrane vesicles are internalized in human host cells and trigger
781 NOD1- and NOD2-dependent NF-kappaB activation. *Infect Immun*, 82, 4034-4046.
782

- 783 van der Ley, P., de Graaff, P. & Tommassen, J. (1986) Shielding of Escherichia coli outer membrane
784 proteins as receptors for bacteriophages and colicins by O-antigenic chains of lipopolysaccharide.
785 J Bacteriol, 168, 449-451.
786
- 787 Vanaja, S.K., Russo, A.J., Behl, B., Banerjee, I., Yankova, M., Deshmukh, S.D.Rathinam, V.A.
788 (2016) Bacterial Outer Membrane Vesicles Mediate Cytosolic Localization of LPS and Caspase-11
789 Activation. Cell, 165, 1-14.
- 790 Vercauteren, D., Vandenbroucke, R.E., Jones, A.T., Rejman, J., Demeester, J., De Smedt,
791 S.C.Braeckmans, K. (2010) The use of inhibitors to study endocytic pathways of gene carriers:
792 optimization and pitfalls. Mol Ther, 18, 561-569.
793
- 794 Wai, S.N., Lindmark, B., Soderblom, T., Takade, A., Westermark, M., Oscarsson, J.Uhlin, B.E.
795 (2003) Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial
796 ClyA cytotoxin. Cell, 115, 25-35.
797
- 798 Wang, L. & Reeves, P.R. (1998) Organization of Escherichia coli O157 O antigen gene cluster and
799 identification of its specific genes. Infect Immun, 66, 3545-3551.
800
- 801 Wang, L.H., Rothberg, K.G. & Anderson, R.G. (1993) Mis-assembly of clathrin lattices on
802 endosomes reveals a regulatory switch for coated pit formation. J Cell Biol, 123, 1107-1117.
803

804 **METHODS**

805 **Bacterial strains and growth conditions**

806 Enterohaemorrhagic *Escherichia coli* (EHEC) Sakai O157:H7, EHEC MA6 (provided by Peter
807 Feng, FDA, Maryland) (Rump et al, 2010) *E. coli* MG1655 and *E. coli* MG1655 L9 with restored
808 O-antigen (Browning et al, 2013) were transformed via electroporation with plasmid pBAD ClyA-
809 Bla (provided by Matthew DeLisa, Cornell University), (Kim et al, 2008). The strains were grown
810 in lysogeny broth (Miller, Sigma), with 50 µg/ml kanamycin, at 37 °C with shaking at 200 rpm.

811

812 **Isolation of outer membrane vesicles by ultracentrifugation**

813 100 ml cultures were grown in LB at 37 °C, with agitation at 200 rpm. Once the OD₆₀₀ reached 0.5-
814 0.6, cells were induced with 0.2% L-arabinose and grown for a further 16 h. Cells were then
815 pelleted at 6000xg, and the supernatants were removed and filtered with a 0.45µm syringe filter.
816 Aliquots of filtered supernatants were spread on LB agar and grown overnight at 37 °C to check
817 that all viable cells had been removed by filtration. 25 ml of filtered supernatants were centrifuged
818 in a Beckman XL90 ultracentrifuge using a 70Ti rotor at 100,000xg (30,000 rpm) for 2 h at 4 °C.
819 After centrifugation, supernatants were removed, and the OMV pellets were resuspended in 1 ml
820 colorless DMEM or sterile water (for TEM) and stored at -20 °C.

821

822 **Isolation of outer membrane vesicles by ExoSpin columns**

823 Strains were grown in 5 ml LB containing 50 µg/ml kanamycin, and induced with 0.2% L-
824 arabinose. Cultures were incubated for 18 h at 37 °C, with shaking at 200 rpm. Cells were pelleted
825 at 6000xg for 5 min, and 1 ml supernatant was then transferred to new tubes and centrifuged at

826 17,200xg for 30 min at 4 °C. 100 µl of supernatant were then added to prepared exospin columns
827 (Cell Guidance Systems) and centrifuged at 50xg for 1 min at 4 °C, and then OMVs were eluted
828 by addition of 100µl PBS to the column and centrifuged at 50xg as before. The purified OMVs
829 were then analyzed for size and concentration using nanoparticle tracking analysis.

830

831 **Nanoparticle tracking analysis**

832 After purification, OMV samples were diluted 1×10^{-6} in filtered sterile PBS. Particle diameter and
833 concentration were measured using the Nanosight LM10 particle tracking analysis, with a
834 minimum of 100 tracks per sample, performed in triplicate. Camera shutter 1495 and gain of 450
835 were used, and size distribution scatter plots were created using GraphPad Prism. Size distribution
836 was analysed using analysis of variance (ANOVA) with a Brown Forsythe test for equal variance.

837

838 **Visualization of outer membrane vesicles by Transmission Electron Microscopy**

839 10µl of isolated outer membrane vesicles in sterile deionized distilled water were added to 400-
840 mesh copper grids, and negatively stained with 4% uranyl acetate for 2 min. Samples were then
841 observed using a Jeol 1200Ex transmission electron microscope (Birmingham Electron
842 Microscopy Facility) with an acceleration of 75kV.

843

844 **Transmission Electron Microscopy of HeLa cells incubated with outer membrane vesicles**

845 HeLa cells (P5) were seeded onto 13 mm coverslips at a concentration of 1×10^5 cells per ml in
846 complete DMEM, 24 h prior to infection. The following day, OMVs were added to the cells for a
847 final concentration of 10 µg/ml protein. The infection proceeded for 0, 30 or 60 min before

848 coverslips were placed in 2.5% glutaraldehyde fixative, and stored at 4 °C before processing and
849 embedding (Birmingham Electron Microscopy Facility). The samples were observed using the Jeol
850 1200 transmission electron microscope, with acceleration at 70kV.

851

852 **Western blotting of EHEC cellular fractions**

853 12 µl of samples normalized for their protein content from EHEC ClyA-Bla and Bla-ClyA whole
854 cell lysate, supernatant and OMV fractions were added to 3µl 5X SDS loading dye and boiled for
855 10 min. Samples were loaded onto a 15 well BioRad pre-cast stain-free SDS-PAGE gel and run at
856 120V, 200mA for 45 min. The gel was then transferred onto a PVDF membrane in transfer buffer
857 containing 20% methanol for 80 minutes at 100V. After transfer, the membrane was blocked at
858 room temperature in TBS 0.1% Tween-20 and 5% skim milk for 1h with agitation. The membrane
859 was washed 3 times with TBS 0.1% Tween-20 (5 min per wash). After blocking, the membrane
860 was incubated with a 1:2000 dilution of mouse anti-Bla primary antibody in TBS 0.1% Tween-20
861 and 5% skim milk overnight at 4 °C with agitation. The following day, the membrane was washed
862 3 times as before, and incubated with a 1:5000 dilution of sheep anti-mouse secondary antibody in
863 TBS 0.1% Tween-20, 5% skim milk for 1h at room temperature with agitation. The membrane was
864 washed again 3 times, and 2 ml BioRad ECL reagents were added to the membrane and incubated
865 for 5 min, before visualization with a BioRad ChemiDoc imager.

866

867 **Protein Quantitation**

868 To quantify levels of protein in cell fractions, the ThermoFisher CBQCA Protein Quantitation kit
869 was used. 10 µl of protein was added to 125 µl 0.1M sodium borate, 5 µl 20 mM KCN, and 10 µl

870 5 mM ATTO-TAG in a 96-well plate, and incubated in the dark for 1-2 h. The fluorescence in
871 samples was measured with an excitation at 465 nm and an emission at 550 nm in a FluoStar
872 OMEGA plate reader. The level of fluorescence in samples was compared to known quantities of
873 bovine serum albumin, and this was used to determine and normalize the protein concentration in
874 cellular fractions.

875

876 **Nitrocefin assay to determine β -lactamase activity**

877 50 μ l of samples were added in triplicate to a 96-well plate. Nitrocefin was diluted to 0.5 mg/ml in
878 PBS and 50 μ l was added to each sample. The absorbance at 486 nm was measured in the FluoStar
879 Omega plate reader for 2 h, and the change in absorbance over time was used to determine the
880 specific activity in samples, using the protein concentration determined by the CBQCA kit.

881

882 **Papain and detergent treatment of OMVs**

883 Triton X-100 and SDS were added at a concentration of 1% to 20 μ l OMVs for 45 min at 37 °C.
884 5ug/ml papain was then added for 30 or 60 min at 37 °C. The papain reaction was inactivated using
885 1 mM PMSF at room temperature for 30 min. 5 μ l SDS-PAGE loading dye was added to the
886 samples, which were then boiled for 10 min. Samples were run on a 15-well pre-cast stain free gel
887 for 45 min at 120V, and then subjected to Western blotting with anti- β -lactamase primary antibody
888 (Pierce) as described above.

889

890

891

892 **LPS staining of OMVs**

893 OMV concentrations were normalised, and 50ul of samples were treated with 5µg/ml proteinase K
894 (Sigma) for 1h at 60 °C to generate LPS only samples. 15µl of treated OMVs were then run on a
895 pre-cast BioRad 12% acrylamide gel at 120V for 1h. The gel was then fixed and stained using the
896 Pierce Silver Stain kit, or the Thermo ProQ Emerald staining kit according to the manufacturers
897 instructions.

898

899 **Cellulase treatment of OMVs**

900 1% cellulase (Sigma) was added to EHEC ClyA-Bla OMVs for 2h at 37 °C, and OMVs were
901 subsequently re-purified by ultracentrifugation.

902

903 **Plate reader FRET experiments**

904 HeLa cells (passage 1-7) were seeded in triplicate in a black-walled, clear bottom 96-well plate at
905 a concentration of 1×10^5 cells per ml in Dulbecco's modified Eagle medium (DMEM)
906 supplemented with 1% L-glutamine, 1% Penicillin/Streptomycin and 10% heat inactivated fetal
907 bovine serum. The plate was incubated at 37 °C, 5% CO₂ for 24 h prior to experiments. The
908 following day, cells were loaded with 20 µl 6X CCF2-AM with 100 µl colourless unsupplemented
909 DMEM (cDMEM) and incubated at room temperature for 1 h in the dark to allow dye loading. The
910 dye was removed by washing 2x in PBS and 1x in cDMEM. Cells were treated with 5 mM methyl-
911 β-cyclodextrin or 1 µg/ml filipin to inhibit cholesterol mediated endocytosis, 80 uM Dynasore for
912 dynamin inhibition, or 20 uM blebbistatin for macropinocytosis inhibition for 1h at 37 °C. Cells
913 were treated with 1 µg/ml chlorpromazine for 1h at 37 °C to inhibit formation of clathrin-coated

914 pits, or with 5 µg/ml papain for 15 min at 37 °C to remove surface proteins, before inactivation of
915 papain with 5 mM PMSF for 20 min. Rough LPS (from *E. coli* EH100 Ra mutant strain, Sigma)
916 or smooth LPS (from *E. coli* O55:B5, Sigma) was added at a concentration of 1µg/ml, and TLR4
917 inhibitor C34 was added at a concentration of 10µM for 30 min at 37 °C prior to co-incubation of
918 OMVs and cells.

919 Reporter OMVs were diluted in cDMEM and added to the cells for a final concentration of 10
920 µg/ml, or 1×10^8 vesicles, corresponding to an MOI of 1000. The plate was immediately placed in
921 the PheraStar plate reader, with excitation at 405 nm and simultaneous dual emission at 530 nm
922 and 460 nm. The wells were scanned (bottom optic) with orbital averaging for a total of 150 cycles,
923 equating to a measurement every 90 seconds for 3 hours. The ratio of blue to green fluorescence
924 intensity detected in the cells at each cycle was calculated using GraphPad Prism, and ratios for
925 uninfected, dye-loaded cells were used as the baseline value for each cycle. All traces were
926 normalized to 0 for their first ratio value. All experiments were performed with a minimum of three
927 technical replicates and three independent repeats.

928

929 **Efficiency of uptake and statistical analysis**

930 Efficiency of uptake was calculated as the total change in blue:green fluorescence intensity ratio
931 after 3h. Student's t-test or ANOVA was used to determine statistical significance of total change
932 between samples. A p value of <0.05 was considered statistically significant.

933

934

935

936 **Rate estimation and statistical analysis**

937 To estimate the gradients of the data, polynomials were fitted to each data set using the cubic spline
938 function *csaps* in Matlab. Numerical estimates of the gradients of the resulting polynomials were
939 determined using the *gradient* function. To ensure that the gradient estimates were as smooth as
940 possible whilst also retaining the overall shape and trend of the data, a small smoothing parameter
941 was used.

942 ANOVA was used to analyse data sets, with a Brown Forsythe test to determine equal variance
943 using GraphPad Prism software. A p-value of <0.05 was considered statistically significant.

944

945 **Confocal Microscopy**

946 HeLa cells (P3-7) were seeded on 13mm coverslips in a 12-well plate at a concentration of 1×10^5
947 cells per ml in complete DMEM, 24 h prior to experiments. The following day, cells were washed
948 and loaded with $100 \mu\text{l}$ 6X CCF2-AM dye with $500 \mu\text{l}$ colourless unsupplemented DMEM, and
949 incubated in the dye solution for 1 h at room temperature in the dark. Cells were then incubated
950 with ClyA-Bla reporter OMVs for 0-4 h. The cells were washed with PBS and then fixed with 0.5
951 ml 4% PFA for 15 min. The next day, coverslips were mounted onto slides with a drop of Gold
952 Anti-Fade mounting solution and then imaged using the Nikon A1R confocal microscope
953 (Birmingham Advanced Light Microscopy Facility), and fluorescence was observed from
954 excitation at 409 nm and dual emissions at 450 nm and 520 nm. Z stacks were produced from 20
955 slices, with gain, exposure and laser intensity kept the same for all slides, and images were taken
956 for 3 representative fields of view per slide. The Z stacks were converted to maximum intensity
957 projection images.

958 Supplemental Information for

959 **Lipopolysaccharide composition determines the preferred route and**
960 **entry kinetics of bacterial outer membrane vesicles into host cells**

961 Eloise O'Donoghue¹, Douglas Browning¹, Ewa Bielska¹, Luke Alderwick¹, Sara Jabbari^{1,2} and

962 Anne Marie Krachler^{3,*}

963

964 ¹Institute of Microbiology and Infection, School of Biosciences, University of Birmingham,

965 Edgbaston, B15 2TT Birmingham, UK

966 ²School of Mathematics, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK

967 ³Department of Microbiology and Molecular Genetics, University of Texas McGovern Medical

968 School at Houston, Houston, TX, 77030, USA.


969 *Correspondence to: Anne Marie Krachler (anne.marie.krachler@uth.tmc.edu)

970

971 **This file contains:**

972 Figures S1-S4.

973




974

975 **Figure S1. Size distribution and concentration of OMVs.**

976 (A) OMVs isolated from EHEC ClyA-Bla (red), MG1655 ClyA-Bla (blue) and MG1655 L9 ClyA-
977 Bla (green) were diluted 1×10^{-6} and analyzed using nanoparticle tracking analysis to determine
978 their size distribution and concentration. Data represents individual tracks, and means \pm stdev from
979 at least 200 tracks per sample. Significance was determined using analysis of variance (ANOVA),
980 with a Brown Forsythe test to determine equal variance. (***) indicates p value of < 0.001 , (**) p
981 < 0.01 .

982 (B) Particle concentrations of OMV preparations isolated from EHEC ClyA-Bla (red), MG1655
983 ClyA-Bla (blue) and MG1655 L9 ClyA-Bla (green) were measured using nanoparticle tracking
984 analysis, then used to dilute OMVs to generate equal MOIs of 1000 (10^8 OMVs/ml) for infection
985 experiments. Results are means \pm stdev from at least 200 tracks per sample. Significance was
986 determined using analysis of variance (ANOVA), with a Brown Forsythe test to determine equal
987 variance. NS indicates no significant differences between samples (p value > 0.05).




988

989 **Figure S2. Characterization of lipopolysaccharide from EHEC wild type, MA6, MG1655 and**
990 **MG1655 L9 strains**

991 OMVs were treated with proteinase K to generate LPS-only samples. EHEC OMVs were also
992 treated with varying concentrations of cellulase to enzymatically remove O-antigen. Isolated LPS
993 was run on pre-cast SDS-PAGE gels and silver stained. High molecular weight bands indicate
994 presence of O-antigen.

995

LPS composition determines OMV entry route into host cells | 45



996
997

Figure S3. Supplementation with exogenous LPS inhibits entry of EHEC OMVs


LPS composition determines OMV entry route into host cells | 46

998 (A) Hela cells were either left untreated (red), or pre-treated with 1ug/ml smooth LPS (lilac) or 1ug/ml
999 rough LPS (violet) and exposed to ClyA-Bla OMVs isolated from EHEC at an MOI of 1000 for 3 hours.
1000 The FRET signal (ratio of blue:green fluorescence) over time was plotted as mean \pm stdev (n=3).
1001 (B) Polynomials were fitted to each data set from (A) using the cubic spline function csaps in Matlab.
1002 Numerical estimates of the gradients of the resulting polynomials were determined using the gradient
1003 function and plotted as means \pm stdev (n=3).
1004 (C) Maximum rates were determined from data in (B) to visualize speed of OMV uptake into untreated Hela
1005 cells (red), or cells pre-treated with 1ug/ml smooth LPS (lilac) or 1ug/ml rough LPS (violet). Data shown
1006 are means \pm stdev (n=3) and significance was determined using ANOVA (****) indicates $p \leq 0.0001$, ns-not
1007 significant ($p \geq 0.05$).
1008 (D) Total FRET changes after 3 hrs were determined from data in (A) and plotted to visualize overall
1009 efficiency of uptake into untreated Hela cells (red), or cells pre-treated with 1ug/ml smooth LPS (lilac) or
1010 1ug/ml rough LPS (violet). Data shown are means \pm stdev (n=3) and significance was determined by
1011 ANOVA (***) indicates $p \leq 0.001$, (**) $p \leq 0.01$.

1012 (E) Hela cells were either left untreated (red), or pre-treated with 1ug/ml smooth LPS (lilac) or 1ug/ml
1013 rough LPS (violet) and exposed to ClyA-Bla OMVs isolated from MG1655 at an MOI of 1000 for 3 hours.
1014 The FRET signal (ratio of blue:green fluorescence) over time was plotted as mean \pm stdev (n=3).

1015 (F) Polynomials were fitted to each data set from (A) using the cubic spline function csaps in Matlab.
1016 Numerical estimates of the gradients of the resulting polynomials were determined using the gradient
1017 function and plotted as means \pm stdev (n=3).
1018 (G) Maximum rates were determined from data in (B) to visualize speed of OMV uptake into untreated Hela
1019 cells (red), or cells pre-treated with 1ug/ml smooth LPS (lilac) or 1ug/ml rough LPS (violet). Data shown
1020 are means \pm stdev (n=3) and significance was determined using ANOVA (****) indicates $p \leq 0.0001$, ns-not
1021 significant ($p \geq 0.05$).
1022 (H) Total FRET changes after 3 hrs were determined from data in (A) and plotted to visualize overall
1023 efficiency of uptake into untreated Hela cells (red), or cells pre-treated with 1ug/ml smooth LPS (lilac) or
1024 1ug/ml rough LPS (violet). Data shown are means \pm stdev (n=3) and significance was determined by
1025 ANOVA (***) indicates $p \leq 0.001$, (**) $p \leq 0.01$.

1026 (I) Hela cells were either left untreated (red), or pre-treated with 1ug/ml smooth LPS (lilac) or 1ug/ml rough
1027 LPS (violet) and exposed to ClyA-Bla OMVs isolated from MG1655 L9 at an MOI of 1000 for 3 hours.
1028 The FRET signal (ratio of blue:green fluorescence) over time was plotted as mean \pm stdev (n=3).
1029 (J) Polynomials were fitted to each data set from (A) using the cubic spline function csaps in Matlab.
1030 Numerical estimates of the gradients of the resulting polynomials were determined using the gradient
1031 function and plotted as means \pm stdev (n=3).
1032 (K) Maximum rates were determined from data in (B) to visualize speed of OMV uptake into untreated Hela
1033 cells (red), or cells pre-treated with 1ug/ml smooth LPS (lilac) or 1ug/ml rough LPS (violet). Data shown
1034 are means \pm stdev (n=3) and significance was determined using ANOVA (****) indicates $p \leq 0.0001$, ns-not
1035 significant ($p \geq 0.05$).
1036 (L) Total FRET changes after 3 hrs were determined from data in (A) and plotted to visualize overall
1037 efficiency of uptake into untreated Hela cells (red), or cells pre-treated with 1ug/ml smooth LPS (lilac) or
1038 1ug/ml rough LPS (violet). Data shown are means \pm stdev (n=3) and significance was determined by
1039 ANOVA (***) indicates $p \leq 0.001$, (**) $p \leq 0.01$.



1040

1041 **Figure S4. Inhibition of TLR4 has no effect on OMV uptake**

1042 (A). HeLa cells were either left untreated (red, green and blue for O157, MG1655 and MG1655 L9
1043 respectively, or pre-treated with 10uM TLR4 inhibitor C34 (lilac, orange and black for O157,
1044 MG1655 and MG1655 L9 respectively) exposed to ClyA-Bla OMVs isolated from O157, MG1655
1045 and MG1655 L9 at an MOI of 1000 for 3 hours. The FRET signal (ratio of blue:green fluorescence)
1046 over time was plotted as mean \pm stdev (n=3).

1047 (B). Total FRET changes after 3 hrs were determined from data in (A) and plotted to visualize
1048 overall efficiency of uptake into untreated HeLa cells (red), or cells pre-treated with C34. Data
1049 shown are means \pm stdev (n=3) and significance was determined by ANOVA. (ns) indicates p value
1050 > 0.05.

1051